Neutrophil-lymphocyte ratio as a predictor of delirium tremens in hospitalized patients with alcohol withdrawal
- PMID: 36709009
- DOI: 10.1016/j.alcohol.2022.12.004
Neutrophil-lymphocyte ratio as a predictor of delirium tremens in hospitalized patients with alcohol withdrawal
Abstract
Delirium tremens (DT) is a severe form of alcohol withdrawal that can be fatal if not recognized early and treated appropriately. In our study, we aimed to determine the role of neutrophil-lymphocyte ratio (NLR), a marker of systemic inflammation, in predicting the development of DT. This retrospective study was conducted in an alcohol and drug treatment center between March 2017 and March 2020. A total of 212 patients with a diagnosis of alcohol use disorder who were admitted to a special care unit after alcohol withdrawal were included. Blood tests were collected within 24 h of the patients' admission. Comparisons were made according to whether the patients developed DT during the hospitalization. DT was diagnosed in 24.1% of the patients. It was determined that higher NLR level (odds ratio [OR]: 4.38, 95% CI: 2.58-7.43) and history of DT (OR: 1.33, 95% CI: 1.23-11.73) are independent risk factors for the development of DT in the logistic regression analysis. The optimal cut-off value of NLR in predicting DT was 2.67 (sensitivity: 82.4%; specificity: 88.8%). The receiver operating characteristic (ROC) curve of NLR showed a larger area under the curve (AUC) than the curves of other systemic inflammation markers. NLR is a simple, practical, and inexpensive marker that can predict the development of DT in patients with alcohol withdrawal syndrome (AWS).
Keywords: alcohol withdrawal; biomarkers; delirium tremens; neutrophil/lymphocyte ratio.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest The authors report there are no competing interests to declare.
Similar articles
-
Plasma neurofilament light chain levels are associated with delirium tremens in patients with alcohol use disorder.Prog Neuropsychopharmacol Biol Psychiatry. 2025 Jan 10;136:111189. doi: 10.1016/j.pnpbp.2024.111189. Epub 2024 Nov 5. Prog Neuropsychopharmacol Biol Psychiatry. 2025. PMID: 39510155
-
Mortality and alcohol-related morbidity in patients with delirium tremens, alcohol withdrawal state or alcohol dependence in Norway: A register-based prospective cohort study.Addiction. 2023 Dec;118(12):2352-2359. doi: 10.1111/add.16297. Epub 2023 Jul 19. Addiction. 2023. PMID: 37465900
-
Risk assessment of moderate to severe alcohol withdrawal--predictors for seizures and delirium tremens in the course of withdrawal.Alcohol Alcohol. 2011 Jul-Aug;46(4):427-33. doi: 10.1093/alcalc/agr053. Epub 2011 May 18. Alcohol Alcohol. 2011. PMID: 21593124
-
[Antipsychotic Treatment of Alcohol Withdrawal Syndrome with Focus on Delirium Tremens: a Systematic Review].Fortschr Neurol Psychiatr. 2025 Jan;93(1-02):36-52. doi: 10.1055/a-2029-6387. Epub 2023 Mar 23. Fortschr Neurol Psychiatr. 2025. PMID: 36958342 German.
-
[Risk factors for delirium tremens: a literature review].Rev Med Interne. 2012 Jan;33(1):18-22. doi: 10.1016/j.revmed.2011.08.002. Epub 2011 Sep 15. Rev Med Interne. 2012. PMID: 21920639 Review. French.
Cited by
-
Biochemical, Hematological, Inflammatory, and Gut Permeability Biomarkers in Patients with Alcohol Withdrawal Syndrome with and without Delirium Tremens.J Clin Med. 2024 May 8;13(10):2776. doi: 10.3390/jcm13102776. J Clin Med. 2024. PMID: 38792318 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical